Questions concerning fertility preservation during transition in girls with Turner syndrome: review of the literature

Małgorzata Więcek1, Jakub Gawlik2, Zuzanna Nowak2 and Aneta Gawlik1

1Department of Pediatrics and Pediatric Endocrinology, Faculty of Medical Sciences, Medical University of Silesia, Katowice, Poland
2Student Scientific Society at the Department of Pathophysiology, Jagiellonian University Medical College, Krakow, Poland

Correspondence should be addressed to A Gawlik: agawlik@sum.edu.pl

Abstract

Loss of fertility is one of the most important concerns facing Turner syndrome (TS) patients as they transition into adult health care. Due to the limited and rapidly decreasing ovarian reserve, many TS patients require fertility preservation (FP) techniques to preserve their reproductive potential until they are ready to pursue procreation. One has to also remember about the additional risks connected with pregnancy in TS patients. In order to determine the optimal time for introducing FP techniques and decrease the chance of an unnecessary intervention, markers and procedures assessing ovarian reserve have been developed. The exposure to potential cardiovascular complications should be determined before FP to avoid unnecessary procedures in patients with potential contraindications to pregnancy. The aim of the present review is to answer the following three questions important for successful preservation of fertility and safe pregnancy in TS: which markers of ovarian reserve should be used as selection criteria for FP? Which methods of FP are the safest and most effective? Are there any cardiovascular contraindications to FP? For each of those questions, separate literature searches have been conducted. A total of 86 articles have been included in this review: 34 for the first question, 35 for the second, and 17 for the third. Ovarian reserve markers and cardiovascular contraindications to pregnancy should be established before FP; however, there are no unambiguous indicators as to which patients should be disqualified from the FP and more evidence is needed in this subject.

Introduction

Turner syndrome (TS) is the most common sex chromosomal abnormality found in females, with the prevalence of about 1 in 2000 to 1 in 2500 live female births (1). It is a result of a partial or complete loss of one of the X chromosomes, and depending on the level of mosaicism (the proportion of affected cells to healthy ones), it can vary in severity (2). Short stature and primary ovarian failure (OF) are the hallmarks of TS, while it can also manifest with cardiac and renal anomalies, autoimmune disorders, and hearing loss (2). Infertility is reported as one of the most important concerns facing TS patients (3), as only about 5% will ever experience spontaneous pregnancy (4, 5). Alongside puberty induction and cardiovascular status, fertility preservation (FP) is one of the most important issues during the transition process in TS. With the advent of assisted reproductive technologies (ARTs), medicine brought new hope for these patients. However, due to the limited and rapidly decreasing ovarian reserve, many of them would not be able to benefit from ART upon reaching adulthood. FP techniques, such as cryopreservation of oocytes or ovarian tissue, introduced at a young age are thus essential in giving these patients a chance at reproduction and parenthood.
As FP techniques are invasive and may cause complications, they should be introduced only when tangible benefit is possible. That is why a number of markers and procedures have been developed to properly assess the ovarian reserve, before attempting FP (6, 7). ART should also be applied with caution, as pregnancy may carry serious risks for TS women. Therefore, the exposure for potential cardiovascular complications should also be determined before the FP to avoid unnecessary procedures in patients with contraindications to pregnancy (2).

The aim of this paper is to sum up the recent literature concerning FP in TS and to establish which factors should be taken into consideration during preparation for the FP procedures.

Material and methods

In our study, we set out to answer three questions important for successful preservation of fertility and safe pregnancy in TS. For each of those questions, separate literature searches have been conducted. Articles have been acquired from PubMed and Embase databases, based on keyword searches (described in detail for each question below), as well as selection criteria, which included: publication date between January 2002 and July 2022, written in English, published in a scholarly peer-reviewed journal. Additional sources were collected from reference lists found in aforementioned articles.

Which markers of ovarian reserve should be used as selection criteria for FP?


Which methods of FP are the safest and most effective?


Are there any cardiovascular contraindications to FP?

Due to finding a sufficient number of original research papers, case reports were excluded from this literature search. Seventeen articles concerning pregnancy outcomes in women with TS were included in this section (Fig. 3). Numbers of TS patients, pregnancies, dilation of aorta

Results

Eighty-six articles were included in this review. Detailed selection process for each question has been presented on flow charts (Figs 1, 2 and 3).

Which markers of ovarian reserve should be used as selection criteria for FP?

Thirty-four articles were used in the preparation of this section (Fig. 1).

Which methods of FP are the safest and most effective?

Thirty-five studies were included in this section (Fig. 2).

Are there any cardiovascular contraindications to FP?

Due to finding a sufficient number of original research papers, case reports were excluded from this literature search. Seventeen articles concerning pregnancy outcomes in women with TS were included in this section (Fig. 3). Numbers of TS patients, pregnancies, dilation of aorta...
(AoD), and the rate of cardiac screening before pregnancy were systematized and presented in Table 1. Table 2 shows the characteristics of women diagnosed with AoD.

Discussion

Which markers of ovarian reserve should be used as selection criteria for FP?

Accelerated follicular depletion and gonadal dysgenesis are the primary characteristics of TS (5). Although the initial migration of primordial germ line cells does not seem to be impaired, patients with TS experience a steep loss of germ cells, with oocyte reserves depleted even in early childhood (7). FP procedures are invasive and come with a certain risk of complications (2); therefore, we should strive for efficient and accurate methods to properly assess the reserve before they are implemented. Below, we analyse the currently available markers and procedures.

Karyotype

Patients diagnosed with mosaicism often present with milder TS stigmata and fewer characteristic pathologies. Generally, mosaic patients (either with 45,X/46,XX or 45,X/47,XXX) more frequently present with spontaneous and cyclical menstruation (8). It is believed that the quantity of oocytes and ovarian function is determined by the degree of mosaicism (proportion of 46,XX cells) in the ovaries (9), with women who have a higher proportion of the 46,XX line achieving more viable oocytes (10) and experiencing OF later in life (11). In a study examining 328 TS patients of various karyotypes, Noordman et al. determined that gonadal dysfunction was the most favourable in 45,X/46,XX mosaic karyotypes in terms of spontaneous puberty (12). Additionally, 70% of the spontaneous pregnancies, seen in 2–5% of the TS population, are observed in 45,X/46,XX mosaic patients (4). Finally in a study by Borgström et al., 45,X/46,XX mosaicism has been determined as the best predictive factor for finding remaining follicles in the ovaries of girls with TS in terms of sensitivity (13). It is, however, worth to mention that even in non-mosaic TS, girls primordial and primary follicles have been observed up to the age of 13 (10) and viable oocytes collection has been documented (14). This phenomenon could be explained by the ‘cryptic mosaicism’ theory (15, 16), which states that all surviving TS embryos diagnosed as non-mosaic 45,X are actually mosaics for a ‘rescue line’ that includes a viable karyotype. Reports show that even in cases when 45,X karyotype is confirmed in lymphocytes, buccal cells, and urine cells,
cryptic mosaicism can still be present in ovarian tissue (17). Taking that into consideration, we propose that non-mosaic karyotype should be treated as a factor negatively affecting chances for finding viable oocytes but not an absolute contraindication for FP.

**Table 1** Summary of the literature analysed for question 3.

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Journal</th>
<th>Year of publication</th>
<th>Type of study</th>
<th>Cases</th>
<th>Pregnancies</th>
<th>Number of dissections</th>
<th>Prepregnancy cardiac screening</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calanchini et al. (80)</td>
<td>Fertility and Sterility</td>
<td>2020</td>
<td>Retrospective</td>
<td>156</td>
<td>32 (18 spontaneous, 7 OD with live birth, 7 OD with miscarriage) 68 pregnancies in 60 women</td>
<td>4/131 nulliparous 0/25 pregnant with live borns</td>
<td>12/25</td>
</tr>
<tr>
<td>Greval et al. (77)</td>
<td>Heart</td>
<td>2021</td>
<td>Retrospective</td>
<td>60</td>
<td>0/68 nulliparous; 0/60 6 months postpartum</td>
<td>128/128</td>
<td></td>
</tr>
<tr>
<td>Kooijman et al. (81)</td>
<td>American Journal of Cardiology</td>
<td>2021</td>
<td>Retrospective</td>
<td>30</td>
<td>0/30</td>
<td>22/30</td>
<td></td>
</tr>
<tr>
<td>Cadoret et al. (82)</td>
<td>European Journal of Obstetrics and Gynecology and Reproductive Biology</td>
<td>2018</td>
<td>Retrospective</td>
<td>103</td>
<td>0/103</td>
<td>49/62 (79%) after 2009 vs 56/93 (60%) before 2009</td>
<td></td>
</tr>
<tr>
<td>Cauldwell et al. (78)</td>
<td>International Journal of Obstetrics and Gynaecology</td>
<td>2021</td>
<td>Retrospective</td>
<td>84</td>
<td>20 (18 with live birth)</td>
<td>73/127 (57.4%)</td>
<td></td>
</tr>
</tbody>
</table>
| Obata et al. (83) | Clinical Pediatric Endocrinology | 2020 | Retrospective | 20 | 0/20 | MRI of the aorta: 5/20 (25%) ECG: 13/20 (65.0%)
| Haddott et al. (84) | Fertility and Sterility | 2011 | Retrospective | 10 | 0/10 | 0/10 |
| Bryman et al. (5) | Fertility and Sterility | 2011 | Retrospective | 57 | 124 | 52 in 27 women (spontaneous) 1/57 (1.75%) No data |
| Donadille et al. (4) | Fertility and Sterility | 2015 | Retrospective | 480 | 0/52 | 25/30 pregnancies All |
| Mercadal (85) | Human Reproduction | 2011 | Retrospective | 23 | 0/23 | No data |
| Doğer et al. (86) | Reproductive Biology and Endocrinology | 2015 | Retrospective | 22 | 0/23 | No data |
| Chevalier et al. (79) | Journal of Clinical Endocrinology and Metabolism | 2011 | Retrospective | 93 | 2/93 (2.2%) | 56/93 (60.2%); echo: 31/93 (33.3%); thoracic MRI: 4/93 (4.3%); aortic diameter: 6/93 (6.4%)
| Deligeoroglou et al. (87) | Journal of Obstetrics and Gynaecology | 2016 | Retrospective | 4 | 0/4 | 56/93 (60.2%); echo: 31/93 (33.3%); thoracic MRI: 4/93 (4.3%); aortic diameter: 6/93 (6.4%)
| Hagman et al. (88) | Human Reproduction | 2013 | Retrospective | 110 | 1/110 (0.9%) | 73/115 (63.5) |
| Hagman et al. (89) | Journal of Clinical Endocrinology and Metabolism | 2011 | Retrospective | 115 | 1/115 (0.87%) | 73/115 (63.5) |
| Bodri et al. (90) | Human Reproduction | 2005 | Retrospective | 21 | 0/12 | All |
| Giles et al. (91) | Fertility and Sterility | 2020 | Retrospective | 166 | 0/93 | All |

OD, oocyte donation.

**Age**

Studies show that the initial migration of germline cells to the genital ridges is undisturbed in TS foetuses (18), and germ cells can be found in ovaries <25th gestational week (GW) (19). Their steep loss is, however, observed
as they enter the early stage of meiotic prophase (20), around the second and third trimesters. Comparing to age-matched controls at 20 GW, the proportion of apoptotic oocytes is markedly higher in TS, reaching even 70% in TS and only 7% in controls (21). This results in a drastically decreased number of germ cells even in the prenatal stage. Additionally, the formation of primordial follicles is often impaired and instead replaced by connective tissue proliferation (19). Total depletion of the oocyte reserve can be already observed in the first years of life in some non-mosaic patients. A recent study asserting the connection between OF and karyotype showed that the median age of OF was 10 years in 45,X patients, with 100% of this karyotype succumbing to OF. In contrast, only 1 out of 13 studied patients with 45,X/46,XX mosaicism (mean 10 years of age) suffered from OF, which was however diagnosed at the age of 4. This study has also established a negative correlation between the proportion of 45,X cells in the peripheral karyotype and age of OF (11).

Assuming a mean age of diagnosis of TS at about 5-7 years of age, this leaves a very limited amount of time to consider FP. In order to ensure the best outcomes, this topic should be discussed as soon as possible after the diagnosis, even in infancy. In mosaic patients, this window of opportunity may be wider, although one cannot forget about possible discrepancies between peripheral and oocyte karyotype determination, which could be responsible for earlier OF in these patients.

**FSH**

Follicle-stimulating hormone (FSH) has been shown to display a biphasic pattern of secretion in TS population independent of studied karyotype (22, 23, 24, 25). It remains elevated from birth to around the age of 5, when it drops to pre-pubertal levels, and increases again at the age of 10, reaching postmenopausal levels a few years later. While the same pattern is observed in healthy girls, there are some clear differences. Most studies agree that in TS patients who suffered from the most severe OF, FSH levels are markedly increased during infancy and at the time of expected puberty (23). Ages 5-10, however, are a point of contention, with earlier publications stating that FSH levels recorded during this time are not elevated compared to pre-pubertal healthy girls (23, 24), while some recent studies using ultrasensitive assays claim that the FSH decline after the age of 5 does not in fact reach normal levels and could be used to diagnose girls with unexplained short stature (22). Nevertheless, diagnosis of OF based on FSH levels can be made only before the age of 5 and in adolescence. Taking into account that with the advent of ovarian tissue cryopreservation (OTC), midchildhood could become a vital time for FP; this poses as a considerable obstacle for using FSH as a viable marker.

Scarc information on the relation between the presence of available oocytes and FSH in TS is available, with most studies describing the adolescent and adult TS populations. In a study by Borgstrom et al., FSH within normal levels for age and stage of puberty predicted the presence of follicles obtained during laparoscopic biopsy with accuracy of 73%, FSH<11 mIU/mL was characterized with 69% sensitivity (second highest sensitivity after mosaic karyotype), and FSH>15 mIU/mL displayed 77% specificity (13). Based on the analysis of cases of oocyte cryopreservation (OC) by Schleedoorn, we can however see that in 8 out of 18 recorded instances of successful oocyte retrieval, FSH before ovarian stimulation was above >15 mIU/mL. Better results are achieved when FSH is combined with other factors, as is shown in a retrospective study by Volodarsky-Perel (26). Combining FSH ≤ 20 mIU/ mL with anti-Mullerian hormone (AMH) > 0.16 ng/mL and ultrasonographic finding of ≥1 antral follicle yielded a 100% success rate of finding follicles in OTC, if ≥2 parameters were positive.

Even though presently we lack sufficient results that would link FSH concentrations with follicle count, a number of longitudinal studies are on the horizon that could shed light on this topic (27, 28).

**AMH**

AMH is secreted by the granulosa cells of preantral follicles in the process of determining the dominant follicle. It has been closely studied in general population with regard to predicting follicular reserve and follicle recruitment (29) and correlates well with antral follicle count in adults (30) and adolescents (31). In younger paediatric patients, reports on this correlation are however inconclusive, with some studies reporting positive correlation (32) and some none (33, 34). In TS, AMH concentrations are higher in patients with spontaneous puberty and mosaic karyotype (35, 36). In a study of TS patients by Borgstrom et al., AMH concentrations above 2 pmol/L (0.28 ng/mL) (accepted norm for teenagers) predicted the presence of follicles in laparoscopic biopsy, with an accuracy of 81%, a sensitivity of 64%, and a specificity of 88% (20). Other studies also used this cut-off point as an indication for oocyte (14) or OTC (26) with good results. However, the low sensitivity makes this marker prone to omission of viable patients; that is why repeated measurements alongside other markers are recommended.
In recent years, AMH has emerged as the dominant marker determining the feasibility of FP. In recommendations by Oktay et al., decrease of AMH <2 ng/mL (14.28 pmol/L) in pre-pubertal girls is an indication for OTC (6), while in recommendations by Nawroth et al., AMH plays an even more prominent role, with AMH <0.5 ng/mL (3.57 pmol/L) being a contraindication for cryopreservation in non-mosaic patients (37).

Inhibin B
Inhibin B is produced by small developing follicles and thus has been proposed as a marker of ovarian reserve. Its concentration decreases earlier than any other marker of ovarian reserve and is more specific to decline in follicle number than inhibin A (38). Detectable levels of inhibin B are present in pre-pubertal girls (at a detection limit of 20 pg/mL), in contrast to most adolescent TS patients without ovarian function (39). In a longitudinal study by Hagen et al., undetectable inhibin B in all measurements throughout childhood predicted premature OF in 20/20 patients, and at least one detectable measurement has been recorded in 9/10 with spontaneous puberty (23). This shows that repeatable inhibin B measurements could be useful in predicting the condition of ovarian reserve; however isolated undetectable concentrations are not an absolute contraindication for FP. No studies are currently available directly correlating inhibin B concentrations with follicle count.

Atrial follicle count
Atrial follicle count (AFC) is an imaging technique which can be performed using transabdominal or transvaginal ultrasonography and MRI. The technique for performing AFC should be determined based on the patients’ age and feasibility of examination, as effectiveness seems to be comparable. AFC has shown a strong positive correlation with AMH among healthy adolescent girls (31, 40), with some studies suggesting its interchangeability. However, when considering FP, especially in younger patients with non-mosaic karyotypes, AFC could provide invaluable first-hand information on the state of the ovarian reserve.

Which methods of FP are safest and most effective?
As previously mentioned, in most women with TS, a decline in ovarian function before reaching reproductive age is observed. Taking into account the limited and

<table>
<thead>
<tr>
<th>Author</th>
<th>Case number</th>
<th>Age of AoD</th>
<th>Karyotype</th>
<th>Heart defect</th>
<th>Maternal outcomes</th>
<th>Fetal outcomes</th>
<th>AFC/aortic food diameter</th>
<th>AMH, inhibin A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cauldwell et al. (78)</td>
<td>1</td>
<td>No data</td>
<td>Healthy</td>
<td>No data</td>
<td>Survived</td>
<td>Stillborn</td>
<td>15</td>
<td>14.28 pmol/L</td>
</tr>
<tr>
<td>Cauldwell et al. (78)</td>
<td>2</td>
<td>No data</td>
<td>Healthy</td>
<td>No data</td>
<td>Died</td>
<td>No data</td>
<td>16</td>
<td>14.28 pmol/L</td>
</tr>
<tr>
<td>Bryman et al. (65)</td>
<td>3</td>
<td>38</td>
<td>Y-chromosome fragment option</td>
<td>No data</td>
<td>Survived</td>
<td>No data</td>
<td>39 mm</td>
<td>14.28 pmol/L</td>
</tr>
<tr>
<td>Chevalier et al. (79)</td>
<td>4</td>
<td>33</td>
<td>BAV, aortic dilation</td>
<td>No data</td>
<td>Died</td>
<td>No data</td>
<td>35 mm</td>
<td>14.28 pmol/L</td>
</tr>
<tr>
<td>Chevalier et al. (79)</td>
<td>5</td>
<td>33</td>
<td>BAV, aortic dilation</td>
<td>No data</td>
<td>No data</td>
<td>No data</td>
<td>Healthy</td>
<td>14.28 pmol/L</td>
</tr>
<tr>
<td>Hagman et al. (88)</td>
<td>6</td>
<td>28</td>
<td>Mosaicism</td>
<td>No data</td>
<td>Survived</td>
<td>No data</td>
<td>30 mm</td>
<td>14.28 pmol/L</td>
</tr>
<tr>
<td>Hagman et al. (88)</td>
<td>7</td>
<td>36</td>
<td>45X, 45X mosaic cells</td>
<td>No data</td>
<td>Survived</td>
<td>No data</td>
<td>Healthy</td>
<td>14.28 pmol/L</td>
</tr>
</tbody>
</table>

AoD, dilatation of the aorta; BAV, bicuspid aortic valve; CoA, coarctation of the aorta.
ever-diminishing ovarian reserve in TS, breaching the topic of FP, evaluating ovarian reserve markers and proposing adequate FP procedures should be of utmost importance.

The main issue limiting the implementation of FP techniques is markedly reduced follicle pool, which can be depleted as soon as in pre-pubertal age (41, 42). As a consequence, it is advised to assess ovarian reserve at the time of diagnosis and, if necessary, quickly introduce FP techniques due to accelerated ovarian aging and considerable risk of primary OF (43). Non-mosaic karyotype is considered as a factor negatively affecting chances for finding viable oocytes in TS patients but not an absolute contraindication for FP. Accordingly, in this group, it is advised to preserve ovarian tissue as early as possible, even in infancy (7). Mosaic patients are believed to have spontaneous and cyclical menstruation (8) and more viable oocytes (10) and experience OF later in life (11). Therefore, 45,X/46,XX mosaic patients are in most cases advised to postpone FP procedures until menarche with a greater chance of succeeding (6, 7).

It is worth to remember that any implementation of FP techniques requires evaluation of the patients’ emotional and physical readiness (44). Additionally, contraindications and risks connected with pregnancy should be discussed, so that an informed decision could be made by the patient or their parent (45).

Currently, only two well-established FP techniques for TS patients with preserved ovarian function are available: OC and embryo cryopreservation (EC). Another experimental technique is being introduced into clinical practice – OTC, applicable in pre-pubertal girls.

Women with exhausted ovarian reserve can be offered other options, which include in vitro fertilization with donor oocytes (IVF-DO), gestational surrogacy, and adoption.

Below, we will focus on techniques which allow for conception of biological offspring, as adoption, oocyte donation, or surrogacy are regulated by each country’s individual law, analysis of which goes beyond the scope of this paper.

**Oocyte cryopreservation**

OC is considered to be a safe and effective technique of FP in women with mosaic TS (46, 47). It is dedicated for post-menarchal girls with normal ovarian function, as it requires gonadotropin stimulation (7). Additionally, its feasibility before menarche is limited because of physical, sexual, or psychosocial immaturity (48). Recently however, a case report by Azem et al. has been published describing a successful retrieval and cryobanking of oocytes in a 7-year-old pre-pubertal TS patient (49). This could provide an alternative for OTC in younger TS patients.

Following the stimulation, ovarian response is monitored with the use of transabdominal ultrasound and serum oestradiol levels (48). Finally, oocyte retrieval is performed transvaginually under general anaesthesia. Transabdominal retrieval is feasible but not recommended (50). In vitro maturation (IVM) is used to increase the yield of mature oocytes. Oocytes are then vitrified, which increases the post-thaw survival (even to 90–95%), comparing to slow freezing (9, 51). Vitrified oocytes show similar fertilization and pregnancy rates compared to fresh oocytes (51). Due to small yields in TS women, additional stimulation cycles are often required for a minimal number of 10 mature oocytes (50). DuoStim, which consists of two cycles of stimulation and oocyte retrieval, could also be used to maximize the yields in TS patients. In a case reported by Ito et al. using DuoStim, 10 and 9 oocytes were retrieved after two stimulation phases during one cycle, approximately doubling the yield (52).

The method also allows for pre-implantation genetic screening, which is important in TS patients, in order to screen out aneuploidic embryos (53).

In patients with preserved menstrual cycles, natural-cycle IVF is available. It is believed that oocytes retrieved from natural cycles might be of better quality and result in a healthier embryo (9) However, it prolongs the process of oocyte retrieval, which may be contraindicated in women with quickly diminishing ovarian function.

In a study by Oktay et al., oocyte stimulation has been performed in three girls with mosaic TS. After an average of 11 days for ovarian stimulation between 7 and 19 oocytes were retrieved, of which 53% were mature. IVM yielded one additional oocyte in one case and five in another. In one case, the procedure had to be repeated due to small number of vitrified mature oocytes. No complications were described.

In another study by Talaulikar et al., OC has been performed in seven women with TS (only one non-mosaic patient). Oocyte retrieval was successful in all women, with a mean of nine oocytes preserved, which was comparable to data from healthy women (46). As in the previous study, no complications were reported.

While the first pregnancy from OC was recorded as far back as in 1986 (54), only very recently we have seen the first TS pregnancy (55). Cryopreservation of 29 oocytes was performed in a mosaic (45,X/46,XX) 25-year-old patient. Post-thaw 23 oocytes survived (79.3%) and 13 were fertilized, resulting in three good quality blastocysts,
two of which were euploid. One was transferred to the uterus, resulting in a healthy live birth. It is however worth to mention that 5 years before IVF, the patient conceived spontaneously and gave birth to a healthy child.

**Embryo cryopreservation**

Although effective and well established in the general population, this method is less frequently performed in TS patients, who usually necessitate FP techniques at a young age, as it requires a sperm donor or a partner. It follows the steps described in OC up to the point of oocyte retrieval (7). The success rate of EC appears to be greater than in OC; however, this difference is negligible in younger patients (56).

In TS, pre-implantation genetic screening of the embryo is advised (57). Additionally, only one embryo should be implanted due to risks connected with pregnancy in TS (58).

Unfortunately, no reports of EC or pregnancies as a result of EC in TS patients have been found.

**Ovarian tissue cryopreservation**

OTC is a new and emerging method, which allows for FP in pre-pubertal girls who cannot wait for OC or EC. This makes it an appealing choice for TS patients, especially those with non-mosaic karyotype or with markedly reduced oocyte reserve in young age. Additionally, it is the only method which allows for preservation of both fertility and endocrine function (9). A panel of international experts in 2020 agreed that OTC should be offered to TS patients but only in a safe and controlled research setting (59).

The procedure involves laparoscopic removal of a part or a whole ovary, cryopreservation of the ovarian cortex, and subsequent auto-transplantation when the patient wants to pursue procreation. Transplantation can be orthotopic, which can even lead to a spontaneous pregnancy, or heterotopic, to s.c. tissue of the abdominal wall, forearm, and chest wall (60). Recent introduction of robot-assisted surgery and use of extracellular matrix scaffolds (AlloDerm) might lead to improvements in outcomes (61).

The effectiveness of OTC in TS patients might however be diminished due to the decreased ovarian reserve even in younger ages. To ensure the best outcomes, a whole ovary should be removed, so as to preserve as much follicles as possible (7, 9). Additionally, as the cryopreservation of the ovarian cortex only preserves the primordial and primary follicles, integrated oocyte aspiration from antral follicles followed by IVM and OC should be used as a supplementary FP technique (43, 62, 63). Finally, to mitigate the oocyte loss connected with hypoxia during transplantation, vasculogenic factors, like sphingosine-1-phosphate (S1P), vascular endothelial growth factor (VEGF), or stromal cell enriched in CD34, could prove useful, although their clinical applicability is still being tested (50, 64, 65).

One has to remember about the disadvantages of OTC. As it involves two surgical interventions, it is characterized with greater risk for the patient than both OC and EC (47). Furthermore, the removal of the ovary for cryopreservation could also decrease chances of spontaneous puberty or accelerate OF (40). Nevertheless, for many patients with TS, it could be the only viable option of FP.

The first case of OTC in TS patients has been described in 2008 by Huang et al. (66), and in 2019 Mamsen et al. reported the outcomes of OTC in 15 girls with TS, ages 5–22.4 years. Oocytes were found in nine girls, of whom only one was non-mosaic at 5 years of age. Most ovaries (6/9) showed a high rate of abnormal follicle morphology. In one mosaic patient, IVM has been performed with 19% success rate, which, while lower than in general population, illustrates that TS oocytes from removed ovarian tissue can reach reproductive potential (67).

Although no pregnancies after OTC in TS patients have been reported, the ever-increasing number of live births from OTC in general population corroborates its effectiveness (68). In 2015, Demestre et al. described a case of pregnancy in a 27-year-old woman, after transplanting cryopreserved ovarian tissue, which was removed at the age of 13, before menarche (55). It was the first reported pregnancy from OTC performed before puberty, which is promising for TS patients from whom ovarian tissue has been harvested at a young age.

A deeper dive into the effectiveness of OCT in TS can be expected upon the publication of an ongoing long-term observational cohort study ‘PROTOCOL’ (27).

**Are there any contraindications to FP?**

Congenital and acquired cardiovascular diseases are directly related to an increased mortality and morbidity incidence in patients with TS (69, 70). Congenital heart defects affect 20–50% of patients with TS. Bicuspid aortic valve (BAV) is observed in approximately 30% of cases, while coarctation of the aorta (CoA) in 7–18% of cases (70). Aortic dilatation occurs in 20–25% of patients with TS, and it can lead to aortic dissection (AoD) which is the most serious cardiovascular complication, with mortality rate reaching 58% (71, 72). Aortic dilatation tends to
occur more frequently in patients with structural heart anomalies (BAV, CoA, and elongated transverse aorta) and hypertension (73). Due to reduced final height in TS women, aortic diameter should be corrected by body surface area. TS-specific Z-score of <2.5 for patients younger than 16 years old or aortic size index (ASI) <2.0 cm/m² in patients older than 16 years old is considered normal aortic size (2).

A special condition affecting the development of severe cardiovascular system complications is pregnancy. Current guidelines by Gravholt et al. suggest that in case of serious aortic dilatation (an ascending ASI of >2.5 cm/m²) or an ascending ASI 2.0–2.5 cm/m² with associated risk factors for aortic AoD (including BAV, CoA, elongated transverse aorta, and hypertension), ART or spontaneous conception should be avoided (2). Those recommendations are consistent with American Heart Association (AHA) statement from 2018 (74). American Society for Reproductive Medicine states that every significant heart abnormality or ASI > 2 cm/m² is an absolute contraindication to pregnancy (75).

Literature analysis was performed to show the prevalence of AoD in pregnant TS women and describe the characteristics of patients in which AoD occurred. This data can be helpful in determining the eligibility for FP; when the decision about the invasive procedure in very young age should be made after excluding the high risk of pregnancy. Current opinion on pregnancy in TS women is based on the study from 2003. Karnis estimated the prevalence of AoD among pregnant TS women as 2% based on analysis of four cases of AoD in pregnant TS women and results of the survey conducted among ART centre (76). Recent studies reviewed in this article present more optimistic data – only seven cases of AoD were described by five authors. In most of the studies, the prevalence of high-risk pregnancies was not established due to poor rate of cardiac screening before conception (Table 1). Grewal et al. described 10 patients (15%) fulfilling the ASRM high-risk pregnancy criteria, with observation of no adverse cardiovascular outcomes reported in this group (77). When analysing the characteristics of pregnant TS women who were diagnosed with AoD (Table 2), it can be seen that dilatation of aorta is not the factor necessary for the occurrence of AoD. Cauldwell et al. described two patients with AoD with normal aortic diameter (78). Patient number 2 (Table 2) described by Chevalier et al. had no cardiac disturbances despite mild aortic insufficiency described in preconceptional echocardiography; however, the enlargement of aortic root (35 mm) was diagnosed at 6 months of pregnancy (79). Those findings show that careful cardiac care during pregnancy is necessary even when the pregnancy is not considered high risk for cardiovascular events. Cabanes et al. recommend cardiac screening at the end of the first and the second trimester and every month of the third trimester. The heart MRI should be performed in case of >10% increase in aortic diameter. If the aortic dilatation is confirmed, patients should be referred to hospital with access to the team of specialists of medical-surgical cardiology, obstetrics, and neonatal intensive care (57).

In conclusion, isolated heart defects should not be contraindication to FP. Vigilance and immediate reaction when there is a risk of cardiovascular complication is crucial while providing the health care of pregnant TS woman.

Conclusions

Eligibility for FP techniques should be established based on multiple factors. Primarily, ovarian reserve markers, and cardiovascular contraindications to pregnancy should be thoroughly analysed prior to any intervention. Among them there are, however, no unambiguous indicators disqualifying the patient from FP. Therefore, the decision should be made weighing the risks of invasive FP techniques and ethical concerns connected with patient’s age, with the chance of successfully preserving the reproductive potential. More evidence is thus needed to properly assess those odds and introduce FP in patients with TS into the standard practice.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

Author contribution statement

M W, J G, Z N, and A G performed literature searches, analysed the database, and wrote the manuscript.

References

in women enrolled in in vitro fertilization cycles: relationship to lifestyle factors, chronological age and reproductive history. Gynecological Endocrinology 2007 23 486–493. [https://doi.org/10.1080/09513590701352815]


35 Ruszała A, Wójcik M & Starzyk J. Evaluation of the usefulness of anti-Müllerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve. Maturitas 2020 134 34–40. [https://doi.org/10.1016/j.maturitas.2020.02.001]


39 Talaulikar VS, Conway GS, Pimblett A & Davies MC. Outcome of ovarian stimulation for oocyte cryopreservation in women with Turner syndrome. Fertility and Sterility 2011 95 9–17. [https://doi.org/10.1016/j.fertnstert.2011.05.019]


53 Schleedoorn MJ, Mulder BH, Braat DDM, Beenderonck CCM, Peek R, Nelen WLDM, Van Leeuwen E, Van der Velden AAEM, Fleischer K & on behalf of the Turner Fertility Expert Panel. International consensus: ovarian tissue cryopreservation in young Turner syndrome patients:


Received in final form 26 September 2022
Accepted 3 October 2022
Accepted Manuscript published online 3 October 2022